BSX Stock Price Today (September 2026) — Boston Scientific Corporation Analysis & Key Metrics 2026-09-03
Boston Scientific Corporation (BSX) is trading at $46.95, down 2.94% today (as of September 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $62.69 (33.5% upside).
- Volatility remains elevated (34.70% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (7.50% YoY) alongside significant competitive pressures.
BSX Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Boston Scientific Corporation - Historical Price & Volume
Market Cap
Enterprise Value: $80.21B
P/E Ratio
Forward P/E: 14.07
Revenue Growth
Year over Year
Analyst Target
+33.5% upside potential
Key Investor Questions About BSX
What investors need to know before buying
Based on current market data, BSX presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 41.60)
- Fundamentals say: Caution warranted (high leverage concerns)
BSX's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BSX investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $12.62B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, BSX stock traded between $42.20 and $109.50—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 34.70% annualized volatility and β=0.53, the stock exhibits low sensitivity to market moves—making BSX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, Boston Scientific (BSX) closed at $46.95, indicating a -2.94% shift from the previous trading day.
Boston Scientific (BSX) Could Be 23% Undervalued After Recalls And Cyber Incident
Boston Scientific (BSX) is back in focus after a series of voluntary global recalls affecting its ENROUTE Transcarotid Neuroprotection Systems and OverStitch Suture Cinch devices, along with a separate cybersecurity incident that has disrupted operations and lowered 2026 guidance. Against this backdrop of recalls and a cybersecurity disruption, Boston Scientific’s recent share price performance has weakened. The stock is at US$48.37 with a year-to-date share price decline of 48.93%, alongside...
Protolabs CEO sees big impact from US reshoring despite potential tariffs
Protolabs (PRLB) CEO and President Suresh Krishna joins Market Domination's Josh Lipton to discuss the Trump administration considering additional semiconductor tariffs and the American reshoring of manufacturing.
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.
Boston Scientific (BSX) Issues Multiple Worldwide Product Recalls
Boston Scientific (NYSE: BSX) has initiated multiple worldwide product recalls, including a Class I recall of its ENROUTE Transcarotid Neuroprotection System due to risks of arterial sheath tip separation. The company has also begun Class II recalls of certain OverStitch Suture Cinch endoscopic devices, citing deployment and suture cutting failures. These recalls affect widely distributed products and introduce added operational, regulatory and reputational pressures for Boston Scientific in...
Boston Scientific (BSX) Stock Looks Cheap After a 55% Slump
Boston Scientific stock has had a steep year, with a sharp share price decline set against valuation checks that point to a potentially cheap entry point based on intrinsic value and market multiples. The stock now screens as undervalued on both a Discounted Cash Flow (DCF) view and on broader valuation metrics, which raises questions about how much of the recent operational setbacks the market has already priced in. Over the past 12 months, Boston Scientific shares have fallen about 55%,...
Cyberattack & Weak 2026 Outlook Weigh on BSX: Is the Stock a Sell?
Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exit.
1 Stock Under $50 to Target This Week and 2 We Ignore
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
The Wide Divide Priced Into Boston Scientific Stock
The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.
2 Reasons to Watch BSX and 1 to Stay Cautious
Boston Scientific has gotten torched over the last six months - since March 2026, its stock price has dropped 36.9% to $48.10 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.
Explore More Analysis for BSX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Boston Scientific Corporation
Boston Scientific Corporation (BSX) is currently trading at $46.95. The RSI (14-day) is at 41.6, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $62.69 implies 33.5% upside from current levels. Volatility is moderate at 34.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Boston Scientific Corporation (BSX): The trailing P/E ratio is 19.01, which is in line with broader market averages. The forward P/E is 14.07, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.67, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 2.72. Price-to-Sales is 3.24. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering BSX, the consensus price target is $62.69. This represents a 33.5% upside from the current price of $46.95. The range spans from a low target of $44.00 to a high target of $94.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Boston Scientific Corporation (BSX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Boston Scientific Corporation (BSX) investors include: 1. Moderate volatility (34.7% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Boston Scientific Corporation's (BSX) current debt and financial health profile: Total debt stands at $12.62B. The debt-to-equity ratio is 50.15, which is moderate and generally manageable for most companies. The current ratio is 1.24, indicating adequate short-term liquidity. The quick ratio is 0.56. The company holds $539.00M in cash and equivalents. Free cash flow is positive at $2.45B, providing a cushion for debt servicing and shareholder returns.